Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine.

Lehr T, Yuan J, Hall D, Zimdahl-Gelling H, Schaefer HG, Staab A, MacGregor TR, Jayadev S.

Pharmacogenet Genomics. 2011 Nov;21(11):721-30. doi: 10.1097/FPC.0b013e32834a522e.

PMID:
21860339
2.

Integration of high-throughput genotyping data into pharmacometric analyses using nonlinear mixed effects modeling.

Lehr T, Schaefer HG, Staab A.

Pharmacogenet Genomics. 2010 Jul;20(7):442-50.

PMID:
20568315
3.

Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine.

Lehr T, Staab A, Trommeshauser D, Schaefer HG, Kloft C.

AAPS J. 2010 Jun;12(2):117-29. doi: 10.1208/s12248-009-9164-6. Epub 2010 Jan 15.

4.

Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole.

Lehr T, Staab A, Trommeshauser D, Schaefer HG, Kloft C.

Clin Pharmacokinet. 2010;49(1):53-66. doi: 10.2165/11317210-000000000-00000.

PMID:
20000889
5.

A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam.

Lehr T, Staab A, Tillmann C, Trommeshauser D, Schaefer HG, Kloft C.

Clin Pharmacokinet. 2009;48(8):529-42. doi: 10.2165/11313370-000000000-00000.

PMID:
19705923
6.

Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach.

Lehr T, Staab A, Tillmann C, Nielsen EØ, Trommeshauser D, Schaefer HG, Kloft C.

Br J Pharmacol. 2008 Jan;153(1):164-74. Epub 2007 Nov 5.

7.

Population Pharmacokinetic Data Analysis of Cilobradine, an I f Channel Blocker.

Fliss G, Staab A, Tillmann C, Trommeshauser D, Schaefer HG, Kloft C.

Pharm Res. 2008 Feb;25(2):359-68. Epub 2007 Jun 21.

PMID:
17587152
8.

Effective integration of systems biology, biomarkers, biosimulation, and modeling in streamlining drug development.

Krishna R, Schaefer HG, Bjerrum OJ.

J Clin Pharmacol. 2007 Jun;47(6):738-43. Epub 2007 Apr 26. No abstract available.

PMID:
17463216
9.

Effective integration of systems biology, biomarkers, biosimulation and modelling in streamlining drug development.

Krishna R, Schaefer HG, Bjerrum OJ.

Eur J Pharm Sci. 2007 May;31(1):62-7. Epub 2007 Feb 20.

PMID:
17408933
10.

Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease.

Lehr T, Staab A, Tillmann C, Trommeshauser D, Raschig A, Schaefer HG, Kloft C.

Br J Clin Pharmacol. 2007 Jul;64(1):36-48. Epub 2007 Feb 23.

11.

Modelling the anti-migraine effects of BIBN 4096 BS: a new calcitonin gene-related peptide receptor antagonist.

Trocóniz IF, Wolters JM, Tillmann C, Schaefer HG, Roth W.

Clin Pharmacokinet. 2006;45(7):715-28.

12.
13.

Quinidine does not affect the renal clearance of moxonidine.

Wise SD, Chan C, Schaefer HG, He MM, Pouliquen IJ, Mitchell MI.

Br J Clin Pharmacol. 2002 Sep;54(3):251-4.

14.

Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure.

Brynne L, McNay JL, Schaefer HG, Swedberg K, Wiltse CG, Karlsson MO.

Br J Clin Pharmacol. 2001 Jan;51(1):35-43.

15.

Comparison of manual versus ambulatory blood pressure measurements with pharmacokinetic-pharmacodynamic modeling of antihypertensive compounds: application to moxonidine.

Trocóniz IF, de Alwis DP, Tillmann C, Callies S, Mitchell M, Schaefer HG.

Clin Pharmacol Ther. 2000 Jul;68(1):18-27.

PMID:
10945312
16.

Population pharmacokinetic-pharmacodynamic modeling of moxonidine using 24-hour ambulatory blood pressure measurements.

Hempel G, Karlsson MO, de Alwis DP, Toublanc N, McNay J, Schaefer HG.

Clin Pharmacol Ther. 1998 Dec;64(6):622-35.

PMID:
9871427
17.

Unusual psychological manifestation of systemic local anesthetic toxicity.

Marsch SC, Schaefer HG, Castelli I.

Anesthesiology. 1998 Feb;88(2):531-3. No abstract available.

PMID:
9477077
18.

Dose-related hemodynamic and electrocardiographic effects of the calcium promoter BAY y 5959 in the presence or absence of congestive heart failure.

Rousseau MF, Massart PE, van Eyll C, Etienne J, Ahn S, Schaefer HG, Mueck W, Bornemann M, Pouleur H.

J Am Coll Cardiol. 1997 Dec;30(7):1751-7.

19.

Pharmacokinetic-pharmacodynamic modelling as a tool to evaluate the clinical relevance of a drug-food interaction for a nisoldipine controlled-release dosage form.

Schaefer HG, Heinig R, Ahr G, Adelmann H, Tetzloff W, Kuhlmann J.

Eur J Clin Pharmacol. 1997;51(6):473-80.

PMID:
9112062
20.

Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients.

Schaefer HG, Stass H, Wedgwood J, Hampel B, Fischer C, Kuhlmann J, Schaad UB.

Antimicrob Agents Chemother. 1996 Jan;40(1):29-34.

21.
22.

Nitrous oxide is a potent cerebrovasodilator in humans when added to isoflurane. A transcranial Doppler study.

Strebel S, Kaufmann M, Anselmi L, Schaefer HG.

Acta Anaesthesiol Scand. 1995 Jul;39(5):653-8.

PMID:
7572016
23.

Pharmacokinetic development of quinolone antibiotics.

Schaefer HG, Ahr G, Kuhlmann J.

Int J Clin Pharmacol Ther. 1995 May;33(5):266-76. Review.

PMID:
7655765
24.
25.

Safety in the operating theatre--part 1: interpersonal relationships and team performance.

Schaefer HG, Helmreich RL, Scheidegger D.

Curr Anaesth Crit Care. 1995;6:48-53.

PMID:
11539933
26.

Human factors and safety in emergency medicine.

Schaefer HG, Helmreich RL, Scheidegger D.

Resuscitation. 1994 Dec;28(3):221-5.

PMID:
7740192
27.

Spinal anaesthesia with 29 gauge Quincke point needles and post dural puncture headache in 2,378 patients.

Dittmann M, Schaefer HG, Renkl F, Greve I.

Acta Anaesthesiol Scand. 1994 Oct;38(7):691-3.

PMID:
7839778
28.

Biopharmaceutical aspects of anti-infective therapy at the extremes of age.

Schaefer HG, Michaelis J.

J Antimicrob Chemother. 1994 Aug;34 Suppl A:33-42. Review.

PMID:
7844072
29.

Prolonged decrease in heart rate variability after elective hip arthroplasty.

Marsch SC, Skarvan K, Schaefer HG, Naegeli B, Paganoni R, Castelli I, Scheidegger D.

Br J Anaesth. 1994 Jun;72(6):643-9.

30.

External ophthalmoplegia after total intravenous anaesthesia.

Marsch SC, Schaefer HG.

Anaesthesia. 1994 Jun;49(6):525-7.

31.

Cerebral vasomotor responsiveness to carbon dioxide is preserved during propofol and midazolam anesthesia in humans.

Strebel S, Kaufmann M, Guardiola PM, Schaefer HG.

Anesth Analg. 1994 May;78(5):884-8.

PMID:
8160985
32.

Haemodynamic response to fibreoptic versus laryngoscopic nasotracheal intubation under total intravenous anaesthesia.

Staender S, Marsch SC, Schumacher P, Schaefer HG.

Eur J Anaesthesiol. 1994 May;11(3):175-9.

PMID:
8050422
33.

Teaching fibreoptic intubation in anaesthetised patients.

Schaefer HG, Marsch SC, Keller HL, Strebel S, Anselmi L, Drewe J.

Anaesthesia. 1994 Apr;49(4):331-4.

34.

The importance of human factors in the operating room.

Schaefer HG, Helmreich RL.

Anesthesiology. 1994 Feb;80(2):479. No abstract available.

PMID:
8311334
36.

Is normal saline an acceptable alternative to silicone for lubricating fibrescopes?

Schaefer HG, Kaufmann MA, Marsch SC, Rudin H.

Eur J Anaesthesiol. 1993 May;10(3):227-30.

PMID:
8495684
37.

Effect of food on the pharmacokinetics of the active metabolite of the prodrug repirinast.

Schaefer HG, Beermann D, Horstmann R, Wargenau M, Heibel BA, Kuhlmann J.

J Pharm Sci. 1993 Jan;82(1):107-9.

PMID:
8381486
38.
39.

Art and anaesthesia.

Schaefer HG, Marsch SC, Kaufmann MA.

Eur J Anaesthesiol. 1992 Nov;9(6):478-9. No abstract available.

PMID:
1425616
40.

Fibreoptic intubation under general anaesthesia need not be associated with hypoxia and hypotension.

Schaefer HG, Marsch SC, Staender S.

Anaesthesia. 1992 Sep;47(9):812-3. No abstract available.

41.

Dreaming and anaesthesia: total i.v. anaesthesia with propofol versus balanced volatile anaesthesia with enflurane.

Marsch SC, Schaefer HG, Tschan C, Meier B.

Eur J Anaesthesiol. 1992 Jul;9(4):331-3.

PMID:
1628637
42.

Perioperative myocardial ischemia in patients undergoing elective hip arthroplasty during lumbar regional anesthesia.

Marsch SC, Schaefer HG, Skarvan K, Castelli I, Scheidegger D.

Anesthesiology. 1992 Apr;76(4):518-27.

PMID:
1550276
43.

Failure of continuous three-channel Holter monitoring to detect acute peri-operative myocardial infarction.

Marsch SC, Castelli I, Schaefer HG, Skarvan K.

Anaesthesia. 1992 Jan;47(1):34-7.

44.

Pharmacokinetics of the active metabolite of the prodrug repirinast in healthy Caucasian volunteers after a single oral dose.

Beermann D, Schaefer HG, Wargenau M, Heibel B, Sturm Y, Kuhlmann J.

Eur J Clin Pharmacol. 1992;42(3):307-12.

PMID:
1315685
45.
46.

Forewarning patients of sexual arousal following anaesthesia.

Schaefer HG, Marsch SC.

Anaesthesia. 1991 Mar;46(3):238-9. No abstract available.

47.

Pronounced bradycardia after application of POR-8 (Ornipressin) under total intravenous anesthesia with propofol.

Marsch SC, Schaefer HG.

Acta Anaesthesiol Scand. 1990 Aug;34(6):514. No abstract available. Erratum in: Acta Anaesthesiol Scand 1991 Jul;35(5):463.

PMID:
2239127
49.

Effects of truncal vagotomy and partial gastrectomy on the pharmacokinetics of propranolol enantiomers in dogs.

Schaefer HG, Harrison D, Hocking MP, Limberg J, Derendorf H.

J Pharm Sci. 1990 Apr;79(4):292-4.

PMID:
2352138
50.

Problems with eye opening after propofol anesthesia.

Marsch SC, Schaefer HG.

Anesth Analg. 1990 Jan;70(1):127-8. No abstract available.

PMID:
2297098

Supplemental Content

Loading ...
Support Center